These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18068495)

  • 21. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Learning lessons from Pfizer's $800 million failure.
    Nat Rev Drug Discov; 2011 Mar; 10(3):163-4. PubMed ID: 21358723
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of CETP inhibition in dyslipidemia.
    El Harchaoui K; van der Steeg WA; Stroes ES; Kastelein JJ
    Curr Atheroscler Rep; 2007 Aug; 9(2):125-33. PubMed ID: 17877921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 26. Illuminating HDL--is it still a viable therapeutic target?
    Rader DJ
    N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168
    [No Abstract]   [Full Text] [Related]  

  • 27. Evacetrapib.
    Nicholls SJ
    Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease.
    Holmes MV; Smith GD
    Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The hypertension peril: lessons from CETP inhibitors.
    Hermann M; Ruschitzka FT
    Curr Hypertens Rep; 2009 Feb; 11(1):76-80. PubMed ID: 19146805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of torcetrapib, a lipid-lowering drug, abandoned.
    Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590910
    [No Abstract]   [Full Text] [Related]  

  • 31. The off-target effects of torcetrapib.
    Funder JW
    Endocrinology; 2009 May; 150(5):2024-6. PubMed ID: 19383878
    [No Abstract]   [Full Text] [Related]  

  • 32. Dyslipidaemia: Is CETP inhibition a viable therapeutic strategy?
    Fernández-Ruiz I
    Nat Rev Cardiol; 2017 Jul; 14(7):382-383. PubMed ID: 28569268
    [No Abstract]   [Full Text] [Related]  

  • 33. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
    Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
    J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Torcetrapib: when global risk reduction goes 'off target'.
    Jackson G
    Int J Clin Pract; 2008 Feb; 62(2):173-4. PubMed ID: 18199271
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.
    Harv Heart Lett; 2007 Mar; 17(7):1-2. PubMed ID: 17378073
    [No Abstract]   [Full Text] [Related]  

  • 37. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK; Ghosh SM
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 39. HDL cholesterol and atherosclerosis.
    Mazzone T
    Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020
    [No Abstract]   [Full Text] [Related]  

  • 40. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
    Briand F; Prunet-Marcassus B; Thieblemont Q; Costard C; Muzotte E; Sordello S; Sulpice T
    Atherosclerosis; 2014 Apr; 233(2):359-362. PubMed ID: 24530763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.